Quant Buys In Cannabis

Quant analysis highlights increasing investment potential in the cannabis sector, with the AdvisorShares Pure US Cannabis ETF (MSOS) recently upgraded to a "buy" due to strong momentum fueled by speculation regarding US federal descheduling. Despite regulatory complexities necessitating investment swaps for US company exposure, MSOS offers significant upside tied to potential legalization. Specific US multi-state operators like Verano Holdings (OTCQX:VRNOF) and Vext Science (OTCQX:VEXTF) are also quant-rated "buys," exhibiting robust valuation, growth, and profitability metrics. However, other prominent players such as Green Thumb (OTCQX:GTBIF) remain "holds" due to weaker growth and negative EPS revisions, underscoring the sector's high-risk, high-reward profile heavily influenced by regulatory developments.

Analysis

The US cannabis sector is currently defined by a significant, momentum-driven rally based on speculation of favorable regulatory changes, specifically the federal descheduling of cannabis which has noted bipartisan support. According to the provided quant analysis, this has propelled the AdvisorShares Pure US Cannabis ETF (MSOS) to a "Buy" rating as of August, a reversal from its prior "Sell" status. MSOS, with approximately $840 million in AUM, offers concentrated exposure to the US market but utilizes a complex swap structure to circumvent federal rules preventing direct ownership of US cannabis stocks, a feature that presents both counterparty risk and the potential for significant upside. At the single-stock level, the quant system identifies specific US multi-state operators (MSOs) as attractive. Verano Holdings (VRNOF) is rated a "Buy" due to its 'A' grade valuation, trading at an 80% price-to-book discount to the healthcare sector, and strong CapEx growth of 98%. Similarly, Vext Science (VEXTF) is a "Buy" based on superior profitability metrics, including an EBITDA margin 76% above the sector. In contrast, the popular MSO Green Thumb (GTBIF) is rated a "Hold" because its strong fundamentals are offset by a failing growth grade, driven by a negative 36% long-term EPS growth forecast, and a high ratio of downward to upward analyst revisions (7 to 1). For investors seeking lower regulatory risk, Canadian operators Tilray (TLRY) and SNDL are rated "Strong Buys" due to their operation in a more mature, federally legal market, though they are less positioned to capture the unique US legalization catalyst.

Key Decisions for Investors

• Investors targeting the US cannabis descheduling catalyst should consider quant-rated 'Buy' instruments like the MSOS ETF for broad exposure or individual operators such as Verano Holdings (VRNOF) and Vext Science (VEXTF) for their strong valuation and profitability profiles.
• Exercise caution with popular MSOs that possess weak forward-looking metrics; for example, Green Thumb (GTBIF) is rated a 'Hold' due to poor growth forecasts and negative analyst revisions, suggesting it may be a longer-term 'wait and see' investment despite its market position.
• When investing in MSOS, be aware that its exposure to US cannabis companies is achieved through swaps, which introduces counterparty risk that must be factored into any investment thesis, as this structure is critical to its pure-play strategy.
• For a less speculative play on the cannabis sector with reduced exposure to US regulatory volatility, consider Canadian 'Strong Buy' rated companies like Tilray (TLRY) and SNDL, which operate in a more mature, federally legal market.